Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Zachary Skrivanek
Observed names:
Z SKRIVANEK,
Z Skrivanek,
Z. Skrivanek
Institution:
Eli Lilly (United States)
Observed institutions:
Eli Lilly (United States),
The Ohio State University
OpenAlex ID:
A5010436601
Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)
2014
·
Michael Nauck
, Ruth S. Weinstock
, et al.
·
Diabetes Care
·
286
Safety and efficacy of once‐weekly dulaglutide versus sitagliptin after 2 years in metformin‐treated patients with type 2 diabetes ( AWARD ‐5): a randomized, phase III study
2015
·
R. S. Weinstock
, B. Guerci
, et al.
·
Diabetes Obesity and Metabolism
·
153
PDF
Dose‐finding results in an adaptive, seamless, randomized trial of once‐weekly dulaglutide combined with metformin in type 2 diabetes patients ( AWARD ‐5)
2014
·
Z. Skrivanek
, B. L. Gaydos
, et al.
·
Diabetes Obesity and Metabolism
·
73
PDF
40th EASD Annual Meeting of the European Association for the Study of Diabetes
2004
·
M. Veitenhansl
, K. Stegner
, et al.
·
Diabetologia
·
70
Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes
2006
·
H. Linnebjerg
, P. A. Kothare
, et al.
·
Diabetic Medicine
·
48
An Adaptive, Dose-Finding, Seamless Phase 2/3 Study of a Long-Acting Glucagon-like Peptide-1 Analog (Dulaglutide): Trial Design and Baseline Characteristics
2012
·
Mary Jane Geiger
, Zachary Skrivanek
, et al.
·
Journal of Diabetes Science and Technology
·
41
Exenatide effects on statin pharmacokinetics and lipid response
2007
·
P.A. Kothare
, H. Linnebjerg
, et al.
·
International Journal of Clinical Pharmacology and Therapeutics
·
36
Low incidence of anti‐drug antibodies in patients with type 2 diabetes treated with once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide
2016
·
Z. Milicevic
, G. Anglin
, et al.
·
Diabetes Obesity and Metabolism
·
34
Application of Adaptive Design Methodology in Development of a Long-Acting Glucagon-like Peptide-1 Analog (Dulaglutide): Statistical Design and Simulations
2012
·
Zachary Skrivanek
, Scott Berry
, et al.
·
Journal of Diabetes Science and Technology
·
32
Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once‐weekly dulaglutide AWARD programme
2015
·
K. M. Dungan
, I. Raz
, et al.
·
Diabetes Obesity and Metabolism
·
17
PDF
Operational Challenges and Solutions with Implementation of an Adaptive Seamless Phase 2/3 Study
2012
·
Kimberly Spencer
, Kelly Colvin
, et al.
·
Journal of Diabetes Science and Technology
·
15
Linkage analysis with sequential imputation
2003
·
Zachary Skrivanek
, Shili Lin
, et al.
·
Genetic Epidemiology
·
10
Network meta-analysis accurately predicted the outcome of a subsequent randomised trial comparing once weekly dulaglutide 1.5 mg and once daily liraglutide 1.8 mg
2016
·
J. L. Fahrbach
, H. Fu
, et al.
·
International Journal of Clinical Practice
·
6
PDF
Safety and Efficacy of Dulaglutide Versus Sitagliptin after 104 Weeks in Type 2 Diabetes (AWARD-5)
2013
·
Bruno Guerci
, Ruth Weinstock
, et al.
·
Canadian Journal of Diabetes
·
6
PDF
Haplotyping using SIMPLE: Caution on ignoring interference
2003
·
Shili Lin
, Zachary Skrivanek
, et al.
·
Genetic Epidemiology
·
5
Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). Diabetes Care 2014;37:2149–2158
2015
·
Michael Nauck
, Ruth S. Weinstock
, et al.
·
Diabetes Care
·
3
PDF
Efficacy of long acting once weekly dulaglutide compared with short acting twice-daily (bid) exenatide in patients with Type 2 diabetes mellitus (T2DM): a post-hoc analysis to determine the influence of baseline HbA1c in the Assessment of Weekly AdministRation of LY2189265 in Diabetes-1 (AWARD-1) trial
2014
·
S Bain
, Z Skrivanek
, et al.
·
Diabetologie und Stoffwechsel
·
3
PII-39Effects of exenatide on statin single-dose pharmacokinetics and 30-week lipid response
2006
·
P KOTHARE
, H LINNEBJERG
, et al.
·
Clinical Pharmacology & Therapeutics
·
3
Efficacy and Safety of Dulaglutide Versus Sitagliptin after 52 Weeks in Type 2 Diabetes (AWARD-5)
2013
·
Michael Nauck
, Ruth Weinstock
, et al.
·
Canadian Journal of Diabetes
·
2
1.7 Efficacy and Safety of Dulaglutide vs. Sitagliptin after 52 Weeks in Type 2 diabetes (AWARD-5) (71-OR)
2013
·
Michael A. Nauck
, Ruth S. Weinstock
, et al.
·
Nederlands Tijdschrift voor Diabetologie
·
2
Efficacy of Once Weekly Dulaglutide Compared with Twice-Daily Exenatide in Patients with Type 2 Diabetes: A Post-Hoc Analysis to Determine the Influence of Baseline HbA1c
2014
·
Steve Bain
, Zachary Skrivanek
, et al.
·
Canadian Journal of Diabetes
A post-hoc pooled analysis of two placebo controlled phase 3 trials, Assessment of Weekly AdministRation of LY2189265 in Diabetes -1 and -5 (AWARD-1 and AWARD-5): dulaglutide compared with exenatide, sitagliptin, and placebo
2014
·
O Adetunji
, Z Skrivanek
, et al.
·
Diabetologie und Stoffwechsel
P303 Efficacité de dulaglutide hebdomadaire à durée d’action prolongée, comparé à l’exénatide à action rapide, administré deux fois par jour chez des patients présentant un diabète de type 2 (DT2) : analyse post-hoc, déterminant l’impact du taux initial d’HbA1
2014
·
S. Bain
, Z. Skrivanek
, et al.
·
Diabetes & Metabolism
PO35 Analyse post-hoc des données poolées de deux essais de phase III contrôlés contre placebo AWARD-1 et AWARD-5 (Assessment of weekly administration of LY2189265 in Diabetes – 1 and – 5/ Évaluation de l’administration hebdomadaire de LY2189265 dans le diabète
2014
·
O. Adetunji
, Z. Skrivanek
, et al.
·
Diabetes & Metabolism
The Application of Drug-Disease and Clinical Utility Models in the Design of AWARD-5: an Adaptive Seamless Phase 2/3 Study
2013
·
Michael Heathman
, Zachary Skrivanek
, et al.
Show more works
View as search
Works count:
28
Citation count:
845
H-index:
11
I10-index:
12
Year
Topic
Type
